Table 3.

Potential neutralizing antibodies targeting SARS-CoV-2

Ab type	Ab name	Ab source	Neutralizing mechanism	Ref.
mAb	CC12.1	Human	Targets the RBD-A epitope	67
	BD-368-2	Human	Overlaps with the ACE2 binding site	68
	B38, H4	Human	Show complete competition with ACE2 for binding to RBD	69
	B5	Human	Binds to the RBD but displays partial competition with ACE2	69
	H2	Human	Binds to the RBD but does not compete with ACE2 for RBD binding	69
	CB6	Human	Is overlapped with the binding epitopes of ACE2	71
	P2B-2F6	Human	Competes with ACE2 for binding to the RBD	71
	31B5	Human	Perturbs the ACE2-RBD interaction	72
	32D4	Human	Perturbs the ACE2-RBD interaction	72
	COVA1-18	Human	Perturbs the ACE2-RBD interaction	73
	COVA2-15	Human	Perturbs the ACE2-RBD interaction	73
	CV30	Human	Inhibits the S-ACE2 interaction	74
	CV1/CV35	Human	Binds to an epitope distinct from the RBD	74
	ADI-55689	Human	Binds at the edge of the ACE2 binding site	76
	ADI-56046	Human	Competes with both hACE2 and CR3022	76
	S309	Human	Targets a conserved glycan-containing epitope within S protein and shows Fc-dependent effector mechanisms	66
	47D11	Transgenic H2L2 mice	Binds to the conserved epitope of RBD without compromising spike-receptor interaction	75
	REGN10987 and REGN10933	Mice and human	Bind to two non-overlapping epitopes of the RBD	89,90
Fc-fusion	VHH-72-Fc	Camelid	Disrupts RBD dynamics and receptor binding	81
Nanobody	n3088, n3130	Human	Targets a cryptic epitope situated in RBD	82
scFv-Fc	5C2	Human	Inhibits ACE2 from binding to S protein	84